Evidence map›Paper›PMID 42619896›Full record

ArticleResearch square2026

FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.

Yogen Saunthararajah, Xiaorong Gu, Sudipta Biswas, Zeinab Zahran, Songa Bae, Ramesh Balusu, Babal Jha, Jaroslaw Maciejewski

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yogen SaunthararajahCleveland Clinic.ORCID 0000-0002-9757-1031
Xiaorong GuTaussig Cancer Institute, Cleveland Clinic.
Sudipta BiswasCleveland Clinic.
Zeinab ZahranAssiut University.
Songa BaeCleveland Clinic.
Ramesh BalusuUniversity of Kansas Medical Center.
Babal JhaCleveland Clinic.ORCID 0000-0002-7660-5255
Jaroslaw MaciejewskiTaussig Cancer Institute, Cleveland Clinic.ORCID 0000-0002-6837-4346

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Targeting Enzymatic Regulation of Fetal Hemoglobin RepressionP01HL146372 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ENGEL, JAMES DOUGLAS · 2019 to 2023
$10.9M
Imaging Liver Cancer ProliferationR01CA204373 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LEE, ZHENGHONG, SAUNTHARARAJAH, YOGEN · 2016 to 2021
$1.8M
PerkinElmer IVIS Spectrum CTS10OD018205 · OD · CLEVELAND CLINIC LERNER COM-CWRU · PI DRAZBA, JUDY · 2015 to 2015
$600k
Operationalizing DNMT1-Targeting to Treat Chemorefractory Pancreatic CancerR21CA263430 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SAUNTHARARAJAH, YOGEN · 2022 to 2023
$409k
NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA204373NCI NIH HHS R21 CA263430NHLBI NIH HHS P01 HL146372NIH HHS S10 OD018205
6 · The paper itself

Abstract

FLT3-ITD mutations in acute myeloid leukemias (AMLs) cause ligand-independent signaling. One way signaling pathways potently and immediately influence cell fates is by phosphorylating key fate-determining proteins to trigger their proteolysis. We investigated the master transcription factor (MTF) driver of granulo-monocytic lineage-fates, CEBPA, for regulation by this mechanism because we found high CEBPA mRNA but little CEBPA protein in

Indexed as

acute myeloid leukemiaCEBPAchemotherapy-resistanceFLT3-ITDp53ubiquitin-proteosome pathwayUSP7

Identifiers

PMID42619896
PMCPMC13484407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.